

Title (en)
GPCRS AS ANGIOGENESIS TARGETS

Title (de)
GPCRS ALS ANGIOGENESE-TARGETS

Title (fr)
RÉCEPTEURS GPCR UTILISÉS COMME CIBLES POUR L'ANGIOGÈNESE

Publication
EP 1996619 A2 20081203 (EN)

Application
EP 07750916 A 20070214

Priority
• US 2007004114 W 20070214
• US 77299106 P 20060214

Abstract (en)
[origin: WO2007095353A2] The invention provides methods of modulating angiogenesis by increasing or decreasing expression or function of G-Protein Coupled Receptors (GPCRs) namely Lectomedin-3 (LEC3), Endothelin-1 Receptor (EDNRA) and C-X-C Chemokine Receptor 4 (CXCR-4). The invention also provides methods of inhibiting and promoting GPCR-dependent angiogenesis in vertebrates, particular mammals, including humans, for the treatment of angiogenesis-related diseases. The invention also provides methods of identifying compounds that promote or inhibit angiogenesis through their interaction with LEC3, EDNRA and/or CXCR-4. The invention further provides methods of modulating angiogenesis through the modulation of these GPCRs and VEGF.

IPC 8 full level
C07H 21/02 (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP)
A61P 1/04 (2017.12); **A61P 9/10** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 33/00** (2017.12); **A61P 35/00** (2017.12); **C07K 14/7158** (2013.01); **C07K 14/723** (2013.01); **A01K 2227/105** (2013.01); **A01K 2267/0306** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK RS

DOCDB simple family (publication)
WO 2007095353 A2 20070823; **WO 2007095353 A3 20090416**; EP 1996619 A2 20081203; EP 1996619 A4 20091118; JP 2009526861 A 20090723

DOCDB simple family (application)
US 2007004114 W 20070214; EP 07750916 A 20070214; JP 2008555380 A 20070214